A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment

Exclusion Criteria

• •1. Knee injections of any type within 6 months prior to the study.
• •2. Inflammatory or auto-immune based joint diseases or other lower extremity pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout)
• •3. Quinolone or Statin induced myopathy/tendinopathy
• •4. Symptomatic lumbar spine pathology (e.g. radicular pain)
• •5. Severe neurogenic inflammation of the cutaneous nerves about the knee or thigh (i.e. evidence of complex regional pain syndrome or central sensitization with allodynia present on exam).
• •6. Contraindications for MRI
• •7. Tested positive or has been treated for a malignancy in the past five years or is suspected of having a malignancy or is currently undergoing radiation or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed injection site
• •8. Condition represents a worker's compensation case
• •9. Currently involved in a health-related litigation procedure
• •10. Is pregnant
• •11. Bleeding disorders
• •12. Currently taking anticoagulant or immunosuppressive medication
• •13. Allergy or intolerance to study medication
• •14. Use of chronic opioid
• •15. Documented history of drug abuse within six months of treatment
• •18\) Any other condition, that in the opinion of the investigator, that would preclude the patient from enrollment